Angiogenesis in life, disease and medicine

Nature

Volumn 438, Issue 7070, 2005, Pages 932-936

  Carmeliet, Peter ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; MEDICINE; PATIENT TREATMENT; TUMORS;

ANGIOGENESIS; IMMUNE DISORDERS;

BLOOD VESSELS;

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB;

BLOOD;

ANGIOGENESIS; BLINDNESS; BLOOD VESSEL; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CIRCULATION; COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; EYE DISEASE; HUMAN; LUNG CANCER; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHEDEMA; NONHUMAN; ORGAN GROWTH; PERICYTE; PREDICTION; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; STROMA CELL;

ANIMALS; BLOOD VESSELS; BONE MARROW CELLS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 30744479430     PISSN: 00280836     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/nature04478     Document Type: Review

References (27)

1. Ny, A. et al. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nature Med. 11, 998-1004 (2005).
2. Carmeliet, P. Angiogenesis in health and disease. Nature Med. 9, 653-660 (2003).
3. Carmeliet, P. & Tessier-Lavigne, M. Common mechanisms of nerve and blood vessel wiring. Nature 436, 193-200 (2005).
4. Lambrechts, D., Storkebaum, E. & Carmeliet, P. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends Mol. Med. 10, 275-282 (2004).
5. Luttun, A., Autiero, M., Tjwa, M. & Carmeliet, P. Genetic dissection of tumor angiogenesis: are PIGF and VEGFR-1 novel anti-cancer targets? Biochim. Biophys. Acta 1654, 79-94 (2004).
6. Simons, M. Angiogenesis: where do we stand now? Circulation 111, 1556-1566 (2005).
7. Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin. Pract. Oncol. (in the press).
8. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
9. Kerbel, R. S. & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nature Rev. Cancer 4, 423-436 (2004).
10. Ostman, A. PDGF receptors - mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15, 275-286 (2004).
11. Song, S., Ewald, A. J., Stallcup, W., Werb, Z. & Bergers, G. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biol. 7, 870-879 (2005).
12. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
13. Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure - an obstacle in cancer therapy. Nature Rev. Cancer 4, 806-813 (2004).
14. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
15. Buttery, R. C., Rintoul, R. C. & Sethi, T. Small cell lung cancer: the importance of the extracellular matrix. Int. J. Biochem. Cell Biol. 36, 1154-1160 (2004).
16. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
17. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
18. Takakura, N. et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 102, 199-209 (2000).
19. Rafii, S. & Lyden, D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nature Med. 9, 702-712 (2003).
20. Grunewald, M. et al. VEGF-induced adult neovascularization depends on SDF-1-mediated retention of bone marrow derived accessory cells. Cell (in the press).
21. Kaplan, R. N. et al. VEGFR1-positive hematopoietic bone marrow progenitors initiate the premestatic niche. Nature 438, 820-827 (2005).
22. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263-274 (2005).
23. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280 (2002).
24. Hirakawa, S. et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201, 1089-1099 (2005).
25. Fletcher, J. A. Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin. Oncol. 31, 4-11 (2004).
26. Gilbert, S. F. Developmental Biology, 6th edn (Swarthmore College, Sinauer Assoc., Sunderland, MA, 2000).
27. Hoyer, M. Untersuchungen ueber das Lymphgefaessystem der Froschlarven. Bull. Acad. Cracov. Teill II, 451-464 (1905).